Literature DB >> 21436340

Tositumomab and iodine I 131 tositumomab (Bexaar).

A Srinivasan1, S K Mukherji.   

Abstract

Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21436340      PMCID： PMC7965875          DOI： 10.3174/ajnr.A2593

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  13 in total

Review 1.  I-131 tositumomab.

Authors:  Basem M William; Philip J Bierman
Journal:  Expert Opin Biol Ther       Date:  2010-08       Impact factor: 4.388

2.  Bexxar, iodine I 131 tositumomab, effective in long-term follow-up of non-Hodgkin's lymphoma.

Authors:  Mark Kaminski
Journal:  Cancer Biol Ther       Date:  2007-07       Impact factor: 4.742

3.  Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.

Authors:  Alan D Dosik; Morton Coleman; Lale Kostakoglu; Richard R Furman; Jennifer M Fiore; Daniel Muss; Ruben Niesvizky; Tsiporah Shore; Michael W Schuster; Patricia Stewart; Shankar Vallabhajosula; Stanley J Goldsmith; John P Leonard
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

4.  Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.

Authors:  Mark S Kaminski; John A Radford; Stephanie A Gregory; John P Leonard; Susan J Knox; Stewart Kroll; Richard L Wahl
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

Review 5.  A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Expert Opin Biol Ther       Date:  2005-04       Impact factor: 4.388

6.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

Authors:  M S Kaminski; A D Zelenetz; O W Press; M Saleh; J Leonard; L Fehrenbacher; T A Lister; R J Stagg; G F Tidmarsh; S Kroll; R L Wahl; S J Knox; J M Vose
Journal:  J Clin Oncol       Date:  2001-10-01       Impact factor: 44.544

7.  131I-tositumomab therapy as initial treatment for follicular lymphoma.

Authors:  Mark S Kaminski; Melissa Tuck; Judith Estes; Arne Kolstad; Charles W Ross; Kenneth Zasadny; Denise Regan; Paul Kison; Susan Fisher; Stewart Kroll; Richard L Wahl
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

Review 8.  Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.

Authors:  F J Rutar; S C Augustine; M S Kaminski; R L Wahl; J A Siegel; D Colcher
Journal:  Clin Lymphoma       Date:  2001-12

Review 9.  Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view.

Authors:  A J Davies
Journal:  Q J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 2.346

10.  I-Tositumomab in lymphoma.

Authors:  M C Cheung; J A Maceachern; A E Haynes; R M Meyer; K Imrie
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677
View more
  7 in total

1.  SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.

Authors:  G Vaidyanathan; B J White; D J Affleck; X G Zhao; P C Welsh; D McDougald; J Choi; M R Zalutsky
Journal:  Bioorg Med Chem       Date:  2012-10-29       Impact factor: 3.641

2.  Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Ming-De Lu; Dian-Chao Yue; Xiao-Yan Xie; Guang-Jian Liu
Journal:  Cancer Biother Radiopharm       Date:  2013-08-21       Impact factor: 3.099

3.  The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Le-Hang Guo; Lin-Na Liu; Feng Lu
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 4.  Target Therapy in Hematological Malignances: New Monoclonal Antibodies.

Authors:  Monika Podhorecka; Justyna Markowicz; Agnieszka Szymczyk; Johannes Pawlowski
Journal:  Int Sch Res Notices       Date:  2014-10-29

Review 5.  Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.

Authors:  Jin Su Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-01-26

Review 6.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 7.  Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Cancer Biol Med       Date:  2014-03       Impact factor: 4.248
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.